Clinical effectiveness of an immunomodulatory drug based on a muramylpeptide composition in the treatment of patients with chronic generalized periodontitis

Grudyanov A.I.; Fomenko E.V.; Kalyuzhin O.V.

doi:https://doi.org/10.17116/stomat20209906124

Grudyanov A.I.

Central Research Institute of Dentistry and Maxillofacial Surgery of Ministry of Health of the Russian Federation

ORCID: 0000-0003-3818-9307

Fomenko E.V.

Central Research Institute of Dentistry and Maxillofacial Surgery of Ministry of Health of the Russian Federation

ORCID: 0000-0003-4747-8039

Kalyuzhin O.V.

I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

ORCID: 0000-0003-3628-2436

Clinical effectiveness of an immunomodulatory drug based on a muramylpeptide composition in the treatment of patients with chronic generalized periodontitis

Authors:

Grudyanov A.I., Fomenko E.V., Kalyuzhin O.V.

More about the authors

Journal: Stomatology. 2020;99(6): 24‑27

DOI: 10.17116/stomat20209906124

Read: 1975 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Grudyanov AI, Fomenko EV, Kalyuzhin OV. Clinical effectiveness of an immunomodulatory drug based on a muramylpeptide composition in the treatment of patients with chronic generalized periodontitis. Stomatology. 2020;99(6):24‑27. (In Russ.)
https://doi.org/10.17116/stomat20209906124

Подписка 2026 Стоматология (Stomatology)

Использование инфографики авторами научных работ

Close metadata

THE AIM OF THE STUDY:

To assess the efficacy of an immunomodulatory drug based on a muramylpeptide composition in the treatment of patients with chronic generalized periodontitis.

MATERIALS AND METHODS

The study comprised 40 patients with chronic generalized periodontitis. In controls the treatment consisted in oral hygiene instructions, professional oral hygiene procedures and root scalling while in main study group the conventional treatment protocol was combined with intramuscular injections of muramylpeptide composition.

RESULTS

The study showed significant reduction of inflammatory symptoms in periodontal tissues in muramylpeptide composition group.

CONCLUSION

Muramylpeptide composition increases the threshold of tissue protection against constantly present microbial accumulations in periodontal disease patients thus providing opportunity for excluding toxic antimicrobial agents and/or antibiotics (or reducing their dosages).

Keywords:

periodontitis

innate immunity

NOD-like receptors

muramyl peptides

Authors:

Grudyanov A.I.

Central Research Institute of Dentistry and Maxillofacial Surgery of Ministry of Health of the Russian Federation

ORCID: 0000-0003-3818-9307

Fomenko E.V.

Central Research Institute of Dentistry and Maxillofacial Surgery of Ministry of Health of the Russian Federation

ORCID: 0000-0003-4747-8039

Kalyuzhin O.V.

I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

ORCID: 0000-0003-3628-2436

Received:

22.04.2020

Accepted:

08.05.2020

Close metadata

References:

Grudjanov AI. Zabolevanija parodonta. M. 2009. (In Russ).
Grudjanov AI, Fomenko EV. Jetiologija i patogenez vospalitel’nyh zabolevanij parodonta. M. 2010. (In Russ).
Tang L, Zhou XD, Wang Q, Zhang L, Wang Y, Li XY, Huang DM. Expression of TRAF6 and pro-inflammatory cytokines through activation of TLR2, TLR4, NOD1, and NOD2 in human periodontal ligament fibroblasts. Arch Oral Biol. 2011;56(10):1064-1072. https://doi.org/10.1016/j.archoralbio.2011.02.020
Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol. 2003;3:710-720.
Selsted ME, Ouellette AJ. Mammalian defensins in the antimicrobial immune response. Nat Immunol. 2015;6:551-557. https://doi.org/10,1038/ni1206
Zorina OA, Berkutova IS, Rehviashvili BA, Ajmadinova NK. Sravnitel’naja harakteristika mikrobiocenozov parodontal’nyh karmanov pri hronicheskom generalizovannom i agressivnom parodontite do i posle kompleksnogo lechenija. Rossijskij stomatologichekskij zhurnal. 2013;1:27-31 (In Russ).
Kaljuzhin OV, Mulik EL, Sergeev VV, Kalina NG, Elkina SI, Kaljuzhina MI, Kuzovlev FN, Karaulov AV. Primenenie ß-geptilglikozid-muramilpeptida v jeksperimental’noj terapii generalizovannyh bakterial’nyh infekcij. Immunopatologija, allergol, infektol. 2019;1:73-77. (In Russ).
Karaulov AV, Kaljuzhin OV. Sfera primenenija muramilpeptidov v ramkah osnovnyh podhodov k immunoterapii/immunoprofilaktike infekcionnyh boleznej. Fiziologija i patologija immunnoj sistemy. Immunofarmakogenomika. 2013;17(5):3-15. (In Russ).
Jan Oscarsson, Rolf Claesson, Mark Lindholm, Carola Höglund Åberg, Anders Johansson. Tools of Aggregatibacter actinomycetemcomitans to Evade the Host Response. J Clin Med. 2019;8(7):1079. https://doi.org/10.3390/jcm8071079
Zhu B, Macleod LC, Newsome E, et al. Aggregatibacter actinomycetemcomitans mediates protection of Porphyromonas gingivalis from Streptococcus sanguinis hydrogen peroxide production in multi-species biofilms. Sci Rep. 2019;9(1):4944. https://doi.org/10.3390/jcm8071079
Chang EH, Giaquinto P, Huang J, Balashova NV, Brown AC. Epigallocatechin gallate inhibits leukotoxin release by Aggregatibacter actinomycetemcomitans by promoting association with the bacterial membrane. Mol Oral Microbiol. 2019;35(1):29-39. https://doi.org/10.1111/omi.12275